Table 3 Study treatment-related AEs for patients with unresectable hepatocellular carcinoma who underwent either HAIC or TACE
Adverse event | Any grade (cases) | Grade 3–4 (cases) | ||||
|---|---|---|---|---|---|---|
HAIC group | TACE group | P | HAIC group | TACE group | P | |
Total | 35 | 41 | 0.110 | 13 | 27 | 0.007 |
Postembolization syndrome | ||||||
 Fever | 7 | 30 | < 0.001 | 0 | 8 | 0.006 |
 Pain | 30 | 27 | 0.219 | 1 | 1 | 1.000 |
 Vomiting | 21 | 18 | 0.371 | 4 | 1 | 0.190 |
Liver dysfunction | ||||||
 Elevated ALT level | 27 | 38 | 0.017 | 1 | 16 | < 0.001 |
 Hypoalbuminemia | 34 | 27 | 0.016 | 0 | 0 | 1.000 |
 Hyperbilirubinemia | 13 | 35 | < 0.001 | 0 | 3 | 0.241 |
Systemic toxicity | ||||||
 Leukopenia | 13 | 8 | 0.203 | 3 | 1 | 0.347 |
 Neutropenia | 6 | 6 | 1.000 | 0 | 1 | 1.000 |
 Anemia | 27 | 25 | 0.477 | 1 | 2 | 1.000 |
 Thrombocytopenia | 13 | 17 | 0.643 | 2 | 4 | 0.676 |
 Anorexia | 30 | 29 | 0.447 | 0 | 0 | 1.000 |
 Diarrhea | 12 | 1 | 0.001 | 1 | 0 | 0.481 |
 Sensory neuropathy | 9 | 1 | 0.006 | 1 | 0 | 0.481 |
Ascites/pleural effusion | 2 | 3 | 1.000 | 1 | 2 | 1.000 |
Cholangitis | 0 | 3 | 0.241 | 0 | 2 | 0.494 |
Hepatapostema | 0 | 1 | 1.000 | 0 | 1 | 1.000 |
Hepatic failure | 0 | 1 | 1.000 | 0 | 1 | 1.000 |
Renal failure | 2 | 5 | 0.434 | 0 | 2 | 0.494 |
Gastrointestinal bleeding | 1 | 2 | 1.000 | 1 | 2 | 1.000 |